GLOBUS MEDICAL INCGMEDEarnings & Financial Report
Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.
GMED Q4 FY2025 Key Financial Metrics
Revenue
$826.4M
Gross Profit
$565.3M
Operating Profit
$169.3M
Net Profit
$140.6M
Gross Margin
68.4%
Operating Margin
20.5%
Net Margin
17.0%
YoY Growth
25.7%
EPS
$1.01
GLOBUS MEDICAL INC Q4 FY2025 Financial Summary
GLOBUS MEDICAL INC reported revenue of $826.4M (up 25.7% YoY) for Q4 FY2025, with a net profit of $140.6M (up 430.4% YoY) (17.0% margin). Cost of goods sold was $261.1M, operating expenses totaled $396.0M.
Key Financial Metrics
| Total Revenue | $826.4M |
|---|---|
| Net Profit | $140.6M |
| Gross Margin | 68.4% |
| Operating Margin | 20.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
GLOBUS MEDICAL INC Q4 FY2025 revenue of $826.4M breaks down across 3 segments, led by Other at $391.8M (47.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $391.8M | 47.4% |
| Nevro Merger Agreement | $293.6M | 35.5% |
| Enabling Technologies | $141.0M | 17.1% |
GLOBUS MEDICAL INC Annual Revenue by Year
GLOBUS MEDICAL INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9B).
GLOBUS MEDICAL INC Quarterly Revenue & Net Profit History
GLOBUS MEDICAL INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $826.4M | +25.7% | $140.6M | 17.0% |
| Q3 FY2025 | $769.0M | +22.9% | $119.0M | 15.5% |
| Q2 FY2025 | $745.3M | +18.4% | $202.8M | 27.2% |
| Q1 FY2025 | $598.1M | -1.4% | $75.5M | 12.6% |
| Q4 FY2024 | $657.3M | +6.6% | $26.5M | 4.0% |
| Q3 FY2024 | $625.7M | +63.1% | $51.8M | 8.3% |
| Q2 FY2024 | $629.7M | +115.9% | $31.8M | 5.0% |
| Q1 FY2024 | $606.7M | +119.3% | $-7.1M | -1.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $606.7M | $629.7M | $625.7M | $657.3M | $598.1M | $745.3M | $769.0M | $826.4M |
| YoY Growth | 119.3% | 115.9% | 63.1% | 6.6% | -1.4% | 18.4% | 22.9% | 25.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $4.94B | $4.99B | $5.09B | $5.25B | $4.71B | $4.96B | $5.10B | $5.30B |
| Liabilities | $1.02B | $1.02B | $1.02B | $1.07B | $623.1M | $665.4M | $696.8M | $729.5M |
| Equity | $3.92B | $3.98B | $4.07B | $4.18B | $4.09B | $4.30B | $4.40B | $4.57B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $52.4M | $54.3M | $203.7M | $210.3M | $177.3M | $77.9M | $249.7M | $248.6M |